Abstract: Glutathione synthetases catalyze the ATP-dependent synthesis of glutathione from L-γ-glutamyl-L-cysteine and glycine. Although these enzymes have been sequenced and characterized from a variety of biological sources, their exact catalytic mechanism is not fully understood and nothing is known about their adaptation at extremophilic environments. Glutathione synthetase from the Antarctic eubacterium Pseudoalteromonas haloplanktis (PhGshB) has been expressed, purified and successfully crystallized. An overall improvement of the crystal quality has been obtained by adapting the crystal growth conditions found with vapor diffusion experiments to the without-oil microbatch method. The best crystals of PhGshB diffract to 2.34 Å resolution and belong to space Refinement of the model, obtained using phases derived from the structure of the same enzyme from Escherichia coli by molecular replacement, is in progress. The structural determination will provide the first structural characterization of a psychrophilic glutathione synthetase reported to date.
Introduction
The tripeptide glutathione (GSH) is the most abundant antioxidant molecule in cells and has multiple biological functions. Besides its protective role in counteracting oxidative free radical species and in the removal of toxic metals, GSH is involved in redox homeostasis, amino acid transport and metabolism of therapeutic drugs, mutagenesis and carcinogenesis; in addition, GSH is also involved in cell cycle regulation, cell signaling, and apoptosis [1] [2] [3] . The synthesis of GSH from its constituent amino acids L-glutamic acid, L-cysteine and glycine involves two ATP-requiring enzymatic steps catalyzed by glutamate cysteine ligase (GshA) and glutathione synthetase (GshB), respectively. In particular, glutathione synthetase catalyzes the synthesis of GSH from the γ-L-glutamyl-L-cysteine and glycine in the presence of ATP and magnesium ion [4] . This process involves the formation of an acyl phosphate on the cysteinyl moiety in L-γ-glutamyl-L-cysteine, followed by the attack of the glycine and formation of an enzyme-product complex, which finally dissociates with the release of GSH, ADP and phosphate (1).
L-γ-glutamyl-L-cysteine + glycine + ATP → GSH + ADP + Pi (1) Glutathione synthetase has been purified, sequenced and characterized from different sources, including yeast [5] , human [6, 7] , rat [8] and Escherichia coli [9] . The comparison of human enzyme with other eukaryotic proteins reveals a high sequence variability, with identity ranging from 18% to 69% [10] . To date, glutathione biosynthesis has never been studied in a psychrophilic source, even though it is known that some antioxidant proteins are covalently modified and likely regulated by cellular thiols (see for example [11] [12] [13] ).
Pseudoalteromonas haloplanktis, a psychrophilic Gram-negative bacterium collected from Antarctic seawater (growth temperature interval, 4-20 °C), produces a glutathione synthetase (PhGshB), whose polypeptide chain is made up of 315 residues, corresponding to a molecular mass of 36 kDa. Sequence alignments show a significant similarity of PhGshB with its mesophilic counterpart from E. coli (69% sequence identity), whose structure has been already determined [14, 15] . With the aim of gaining insights on the mechanism of cold adaptation of glutathione synthetases and to shed light on the exact mechanism of catalytic action of these enzymes, we have undertaken the structural and functional characterization of PhGshB. In this article, we describe the expression, purification, crystallization and preliminary X-ray diffraction studies of the protein. We found that the adaptation of crystallization conditions found using vapor diffusion experiments to a modified microbatch method significantly improves the size and the diffracting power of PhGshB crystals.
Results and Discussion

Crystallization of PhGshB
A recombinant form of PhGshB (rPhGshB) with the C-terminal lysine replaced by the extrapeptide Leu-Glu-His 6 -tag, LE(H) 6 , has been successfully expressed, purified and crystallized using vapor-diffusion and small-scale batch (microbatch) methods. The purified rPhGshB showed a single band of approximately 36 kDa on SDS-PAGE, which is in good agreement with the theoretical molecular mass predicted by the amino acid sequence. Initial screenings using commercially available solutions (Crystal Screen kits I and II, and Index kit from Hampton Research, Laguna Niguel, USA, www.hamptonreaserch.com) revealed several promising conditions for the crystallization of rPhGshB. All favorable conditions were characterized by the presence of polyethylene glycol as precipitating agent. In particular, cubic and rod-like crystals appeared within 2-5 days using a 20 mg mL 
Preliminary X-ray diffraction data showed that cubic crystals are intrinsically disordered and that the largest rod-like crystals obtained by vapor diffusion diffract at most at 3.5 Å resolution, they belong to the space group P2 1 2 1 2 1 , with unit-cell parameters a = 82.81 Å, b = 119.94 Å, c = 159.32 Å. Further optimization of the crystallization conditions to grow larger and thicker crystals suitable for diffraction data collection at high resolution were performed using the microbatch method. This procedure consists of slowly and thoroughly mixing the precipitant with the protein and then placing the mixture in a well-sealed container. Usually the drop is incubated under silicon oil to prevent too rapid dehydration [16] . The benefits of microbatch have been well documented [16, 17] . In the present case, a modified microbatch method, that we define without-oil microbatch, has been used: the drop is stored in the presence of a reservoir with the same precipitant concentration, to avoid drop evaporation [18] . A similar microbatch technique, which does not utilize oil (Small-Scale Batch without Oil) has been developed at the University of Wisconsin [19] , and has been successfully used for many years, though no claim is made for its originality. As reported in other cases [18, 19] , we found that crystallization occurred using 60%-80% of the concentration of the precipitant required in the hanging drop experiment. The best crystals of rPhGshB (maximum size of 0. 
Experimental Section
Expression and Purification of rPhGshB
The putative gene encoding GshB in P. haloplanktis (PhgshB; ID 3708001) [21] was amplified by PCR using specific oligonucleotides allowing its cloning in the pET-28a(+) vector. The forward and reverse primers used were 5′d-A -12 AGGCACAGCCC•ATG•GCA•ATT 9 -3′ and 5′d-A 960 AC•GCT•AAC•CTC•GAG•AGC•GAG•TCG•T 936 -3′, respectively. Numbering in primers begins from starting codon (italics), whereas underlined letters indicate mismatches introduced to create the NcoI and XhoI restriction sites. The amplified segment was digested with NcoI and XhoI and cloned in pET-28a(+) previously digested with the same endonucleases. The new construct was controlled by nucleotide sequencing and used to transform the E. coli BL21(DE3) strain. A culture of this transformant was grown at 37 °C up to 0.6 OD 600 and the heterologous expression was induced for 2 h upon the addition of 0.1 mg mL −1 isopropyl--thiogalactopyranoside. Bacterial cells were collected by centrifugation, resuspended in 20 mM Tris-HCl buffer pH 7.8, and then lysed by a French Press (Aminco, USA) to obtain a cell homogenate. This sample was then centrifuged at 30,000 × g for 1 h and the supernatant was used as starting material for the purification by affinity chromatography on Ni-NTA agarose of rPhGshB, which had the C-terminal lysine replaced by the extrapeptide LE(H) 6 . To this aim, the supernatant was added in batch to the Ni-NTA Agarose resin, equilibrated in 20 mM Tris-HCl buffer pH 7.8. After incubation overnight at 4 °C, the slurry was poured in a column, which was extensively washed with the same buffer supplemented with 10 mM imidazole-HCl. The bound rPhGshB was then eluted with 20 mM Tris-HCl buffer pH 7.8 supplemented with 50 mM imidazole-HCl and pure protein fractions, as analysed by SDS-polyacrylamide gel elecrophoresis, were pooled together, concentrated by ultrafiltration, and stored at −20 °C in 20 mM Tris-HCl buffer pH 7.8 supplemented with 50% (v/v) glycerol. Nearly 20 mg of pure rPhGshB were obtained from a 1 L culture of the transformant.
Crystallization of rPhGshB
Purified rPhGshB was concentrated to 40 mg mL −1 in 20 mM Tris-HCl pH 7.8. Crystallization was performed at 20 °C by the hanging-drop vapor-diffusion method with 0.2 µL of protein and 0.2 µL of reservoir. The following commercially available screens were used: Crystal Screen kits I and II, and Index kit from Hampton Research. Optimization of the crystallization conditions was performed by fine-tuning the protein and precipitant concentrations using a drop consisting of 0.5 µL protein solution and 0.5 µL precipitant solution and a reservoir volume of 500 µL.
Cubic crystals were obtained within 2-5 days from drops containing rPhGshB (20 mg mL −1 in 10 mM Tris-HCl pH 7.8) 30% w/v MPEG 2K and 0.1 M potassium thiocyanate, whereas rod-like crystals were obtained using the same protein solution and a precipitant solution containing 25% w/v PEG 3350 and 0.1 M HEPES pH 7.5. An improvement in the quality of crystals was obtained using different salts and precipitant agents. In particular, well-shaped crystals were grown using 10% w/v PEG 20K, 5% v/v tacsimate, 0.1 M HEPES pH 7.5 as a precipitant solution. However, these crystals only diffract at 3. 
Data collection and Processing
Preliminary diffraction data (3.5 Å resolution) on the rod-like crystals obtained by vapor diffusion were collected at the Institute of Biostructures and Bioimages (Naples, Italy), at 100 K using a Rigaku MicroMax-007 HF generator producing Cu Kα radiation and equipped with a Saturn944 CCD detector.
Higher resolution data (2.34 Å) were collected at 100 K on the crystals obtained by without-oil microbatch at the synchrotron beamline XRD1 of Elettra (Trieste, Italy). Cryoprotection of the crystals was achieved by rapid soaking (1-2 s) in a solution consisting of 12% w/v PEG 20K, 0.1 M HEPES buffer pH 7.5, 5% v/v tacsimate, 30% v/v glycerol. An oscillation range of 0.5° and an X-ray dose corresponding to about 5 s exposure were adopted for all experiments. The data sets were indexed, processed and scaled using the HKL-2000 program package (Table 1 ) [22] . The precision-indicating merging R-factors (R pim and R rim ) were calculated using the program RMERGE [23, 24] .
Structure Determination
The structure of the enzyme was solved by molecular replacement techniques using the program Phaser [25] and the single chain structure of GshB from E. coli as search model (PDB code 1GSA [14] ). To avoid bias, ligands and water molecules were removed from the model prior to structure factors and phases calculation. The solution had an R-factor of 0.39.
Conclusions
In the current study, the glutathione synthetase from the Antarctic eubacterium Pseudoalteromonas haloplanktis was crystallized, X-ray diffraction data collected and the phase problem solved.
An overall improvement of the crystal quality was obtained by adapting the crystal growth conditions found with vapor diffusion experiments to the without-oil microbatch method. In general, the more stable the system in the crystallization process, the higher is the quality of the crystals. These conditions are better realized in the microbatch method, where the crystallization components are mixed to their final concentration at the beginning of the experiment. A significant drawback of the under-oil microbatch method is the slow evaporation of water from the crystallization drops resulting sometimes in the formation of salt deposits that interfere with protein crystal growth. Our results, together with recent literature data [18, 19] , suggest that the adaptation of crystallization conditions to without-oil microbatch method could be a general strategy to convert poorly diffracting crystals into diffraction-quality ones, but further studies are needed to test the validity of this hypothesis.
